Clinical trials
Peripheral Nervous System Diseases clinical trials
Below are recruiting peripheral nervous system diseases clinical trials, each written for real people, not researchers. We’re tracking 64 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06316791RecruitingEarly Phase 1
CNCT19 CAR-T therapy for refractory autoimmune diseases
This early-phase study tests a new CAR-T cell therapy (CNCT19) for people with certain autoimmune diseases that have not responded to standard treatments. It targets a protein called CD19 on immune cells to help reset the immune system and reduce disease activity.
Zhengzhou, HenanAges 18–70 - NCT07640542RecruitingEarly Phase 1
Brain imaging study for Parkinson's and MSA patients
This early-stage research trial tests a new brain-imaging tracer called [11C]MODAG-005 to help doctors better understand Parkinson's disease (PD) and multiple system atrophy (MSA). You would undergo PET/CT and MRI scans twice, a few weeks apart, to see how reliable the imaging is.
Tübingen, Baden-WurttembergAges 50–75 - NCT07023588RecruitingPhase 2
Optimizing AML treatment based on early response
This trial tests if adjusting chemotherapy based on early signs of leukemia can improve outcomes for people newly diagnosed with acute myeloid leukemia (AML). It might be a good fit if you are starting treatment and have a certain level of leukemia cells in your blood after a few days of therapy.
Changchun, JilinAges 18 years+ - NCT07283822RecruitingPhase 2
Pembrolizumab and Ruxolitinib for Lymphoma
This trial is testing two drugs, pembrolizumab and ruxolitinib, together for people with certain types of lymphoma that have come back or not responded to at least one prior treatment. The goal is to see if this combination can help control the lymphoma.
New York, New YorkAges 18–95 - NCT07356245RecruitingPhase 2
Ruxolitinib after stem cell transplant for T-cell lymphoma
This trial tests whether taking ruxolitinib after a stem cell transplant can help prevent T-cell lymphoma from coming back. It is for patients whose lymphoma is in remission (partial or complete) after their transplant.
Columbus, OhioAges 18 years+ - NCT07249346RecruitingPhase 2
Preventing GVHD after stem cell transplant with three drugs
This trial tests a three-drug combination (cyclophosphamide, tacrolimus, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for people with certain blood cancers who have a matched donor and can tolerate high-dose chemotherapy.
Columbus, OhioAges 18 years+ - NCT07696832Recruiting
Ivonescimab as first treatment for advanced lung cancer
This trial studies ivonescimab alone as a first treatment for people with advanced non-small cell lung cancer (NSCLC) that tests positive for PD-L1 and doesn't have certain gene changes. The goal is to see if it works and is safe in everyday medical practice.
Guangzhou, GuangdongAges 18 years+ - NCT07184450RecruitingPhase 1
CAR-T cell therapy for children with hard-to-treat rheumatic diseases
This trial tests a new treatment using your child's own immune cells, modified to target B cells and fight severe rheumatic diseases like juvenile dermatomyositis, arthritis, scleroderma, or Sjogren's syndrome. It's for children who haven't improved with standard treatments.
Hangzhou, ZhejiangAges 5 years+ - NCT00001372Recruiting
Understanding Lupus: Research Study at NIH
This research study aims to better understand systemic lupus erythematosus (SLE), an autoimmune disease where the body's immune system attacks its own tissues. Researchers will evaluate patients with lupus, study genetic factors, and perform optional imaging tests to learn how the disease affects blood vessels and the heart.
Bethesda, MarylandAges 3–120 - NCT07253129Recruiting
Stem cell transplant study for T-cell lymphoma patients with partial response
This study compares two types of stem cell transplants (from a donor or your own cells) for people with certain T-cell lymphomas who had only a partial response to first chemotherapy. It aims to see which approach may work better.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05958719RecruitingPhase 2
Chidamide plus chemotherapy for new nodal TFH cell lymphoma
This trial studies whether adding chidamide to a combination chemotherapy plan (azacitidine, liposomal mitoxantrone, and prednisone) works better for people newly diagnosed with nodal T-follicular helper (TFH) cell lymphoma. It’s testing a treatment strategy after diagnosis to improve disease control and outcomes.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06244368RecruitingPhase 2
Chemo combo for relapsed aggressive lymphoma
This trial tests a combination of chemotherapy drugs (GVM, with or without rituximab) for people whose aggressive non-Hodgkin lymphoma has returned or not responded to standard treatment. It aims to find a new option that might work when others have stopped working.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT06724029Recruiting
Neurosurgery outcomes research for multiple conditions
This study collects data from people having brain or spine surgery for many different conditions. It aims to understand how well different treatments work and how people recover. If you are scheduled for certain brain, spine, or nerve surgeries, you may be able to join.
Bergamo, BGAges 18 years+ - NCT04234048RecruitingPhase 1
ST-001 trial for stubborn T-cell lymphoma that came back
This Phase 1 trial tests ST-001, an experimental treatment, for T-cell lymphomas that have returned or did not respond to prior therapy. It aims to find a safe dose and see whether it can shrink or control the lymphoma.
Scottsdale, ArizonaAges 18 years+ - NCT03970096RecruitingPhase 2
Reduce graft-versus-host disease after stem cell transplant
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
Tampa, FloridaAges 1–60 - NCT05805605RecruitingPhase 2
Low-intensity stem cell transplant with donor cells and blood-protection
This Phase 2 study tests a low-intensity bone marrow/stem cell transplant using a matched donor plus two medicines to help prevent the donor cells from attacking you. It aims to treat certain blood cancers—especially when standard treatment has not fully worked or when you are in remission but at higher risk.
Minneapolis, MinnesotaAges Up to 75 years
Hear when a new Peripheral Nervous System Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for peripheral nervous system diseases?
- Yes. Clin2 currently lists 64 recruiting peripheral nervous system diseases studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a peripheral nervous system diseases trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a peripheral nervous system diseases trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.